CLORPRES (clonidine hydrochloride and chlorthalidone) ® is generally well tolerated. Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are dry mouth, occurring in about 40 of 100 patients; drowsiness, about 33 in 100; dizziness, about 16 in 100; constipation and sedation, each about 10 in 100. In addition to the reactions listed above, certain less frequent adverse experiences, which are shown below, have also been reported
in patients receiving the component drugs of CLORPRES (clonidine hydrochloride and chlorthalidone) ® but in many cases patients were receiving concomitant medication and a causal relationship has not been established:
Gastrointestinal:Nausea and vomiting, about 5 in 100 patients;
anorexia and malaise, each about 1 in 100; mild transient abnormalities in liver
function tests, about 1 in 100; rare reports of hepatitis; parotitis, rarely.
Metabolic: Weight gain, about 1 in 100 patients; gynecomastia,
about 1 in 1000, transient elevation of blood glucose or serum creatine phosphokinase,
Central Nervous System: Nervousness and agitation, about 3 in
100 patients; mental depression, about 1 in 100; headache, about 1 in 100; insomnia,
about 5 in 1000. Vivid dreams or nightmares, other behavioral changes, restlessness,
anxiety, visual and auditory hallucinations and delirium have been reported.
Cardiovascular: Orthostatic symptoms, about 3 in 100 patients;
palpitations and tachycardia, and bradycardia, each about 5 in 1000. Raynaud's
phenomenon, congestive heart failure, and electrocardiographic abnormalities,
i.e., conduction disturbances and arrhythmias, have been reported rarely. Rare
cases of sinus bradycardia and atrioventricular block have been reported, both
with and without the use of concomitant digitalis.
Dermatological:Rash, about 1 in 100 patients; pruritus, about
7 in 1000; hives, angioneurotic edema and urticaria, about 5 in 1000, alopecia,
about 2 in 1000.
Genitourinary: Decreased sexual activity, impotence and loss
of libido, about 3 in 100 patients; nocturia, about 1 in 100; difficulty in
micturition, about 2 in 1000; urinary retention, about 1 in 1000.
Other: Weakness, about 10 in 100 patients; fatigue, about 4 in
100; discontinuation syndrome, about 1 in 100; muscle or joint pain, about 6
in 1000 and cramps of the lower limbs, about 3 in 1000. Dryness, burning of
the eyes, blurred vision, dryness of the nasal mucosa, pallor, weakly positive
Coombs' test, increased sensitivity to alcohol and fever have been reported.
Gastrointestinal: Anorexia, gastric irritation, nausea, vomiting,
cramping, diarrhea, constipation, jaundice (intrahepatic cholestatic jaundice),
Central Nervous System: Dizziness, vertigo, paresthesias, headache,
Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, aplastic
Dermatologic-Hypersensitivity: Purpura, photosensitivity, rash,
urticaria, necrotizing angiitis (vasculitis) (cutaneous vasculitis), Lyell's
syndrome (toxic epidermal necrolysis).
Cardiovascular: Orthostatic hypotension may occur and may be
aggravated by alcohol, barbiturates or narcotics.
Other Adverse Reactions: Hyperglycemia, glycosuria, hyperuricemia,
muscle spasm, weakness, restlessness, impotence.
Whenever adverse reactions are moderate or severe, chlorthalidone dosage should be reduced or therapy withdrawn.